Fig. 3From: Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysisMeta-analysis of finerenone and GLP1-RA trials on MACE. (A) Meta-analysis of finerenone and GLP1-RA trials on MACE stratified by drug class. (B) Meta-analysis of finerenone and GLP1-RA trials on MACE stratified by established atherosclerotic cardiovascular disease (ASCVD). Forest plot showing the treatment estimates of each drug class in each subgroup using random effectsBack to article page